| 9.1599 0.16 (1.78%) | 11-29 10:21 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 14.11  |
1-year : | 17.34 |
| Resists | First : | 12.08 |
Second : | 14.85 |
| Pivot price | 10 |
|||
| Supports | First : | 7.59 | Second : | 6.32 |
| MAs | MA(5) : | 9.21 |
MA(20) : | 10.89 |
| MA(100) : | 15.44 |
MA(250) : | 17.3 |
|
| MACD | MACD : | -1.4 |
Signal : | -1.3 |
| %K %D | K(14,3) : | 25.2 |
D(3) : | 24.2 |
| RSI | RSI(14): 34.4 |
|||
| 52-week | High : | 28.25 | Low : | 7.59 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ HROW ] has closed above bottom band by 41.2%. Bollinger Bands are 73.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 10 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 9.14 - 9.19 | 9.19 - 9.25 |
| Low: | 8.58 - 8.63 | 8.63 - 8.7 |
| Close: | 8.89 - 8.99 | 8.99 - 9.1 |
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Wed, 29 Nov 2023
Harrow Completes Transfer of the TRIESENCE® New Drug ... - Tullahoma News and Guardian
Fri, 17 Nov 2023
Opaleye Management Inc. Bolsters Position in Harrow Inc. with Recent Acquisition - Yahoo Finance
Tue, 14 Nov 2023
Stocks Surge as Soft CPI Report Bolsters Speculation Fed Is Done ... - Nasdaq
Tue, 14 Nov 2023
Harrow Health, Inc. (NASDAQ:HROW) Q3 2023 Earnings Call Transcript - Yahoo Finance
Wed, 18 Oct 2023
Implications Of Harrow's Short Term Guidance (NASDAQ:HROW) - Seeking Alpha
Fri, 29 Sep 2023
Harrow Health, Inc. Changes Corporate Name to Harrow, Inc. - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers—Specialty & Generic
|
|
| Shares Out | 35 (M) |
| Shares Float | 25 (M) |
| Held by Insiders | 6.2 (%) |
| Held by Institutions | 65.3 (%) |
| Shares Short | 6,260 (K) |
| Shares Short P.Month | 5,130 (K) |
| EPS | -0.44 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.16 |
| Profit Margin | -12.5 % |
| Operating Margin | 5 % |
| Return on Assets (ttm) | 1.1 % |
| Return on Equity (ttm) | -37.3 % |
| Qtrly Rev. Growth | 50 % |
| Gross Profit (p.s.) | 1.79 |
| Sales Per Share | 3.25 |
| EBITDA (p.s.) | 0.35 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -162 (M) |
| PE Ratio | -21.32 |
| PEG Ratio | -1.2 |
| Price to Book value | 4.34 |
| Price to Sales | 2.88 |
| Price to Cash Flow | -38.44 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|